2-METHYLIMIDAZOLE; 693-98-1; 2-Methyl-1H-imidazole; 1H-Imidazole, 2-methyl-; Imidazole, 2-methyl-; 2-methyl imidazole; CHEMBL293391; DTXSID4022107; T0049Z45LZ; NSC-21394; 2MZ; NCGC00091456-01; 2-Methylglyoxaline; DTXCID202107; methylimidazole; 2-Methyl-1H-imidazole; 1H-2-Methylimidazole; 2-Methylimidazole; 2MI; 2MZ; 2MZ-H; CAS-693-98-1; CCRIS 2459; EINECS 211-765-7; MFCD00005190; NSC 21394; methylimidazol; Methyl imidazol; UNII-T0049Z45LZ; 2methylimidazole; methyl-imidazole; AI3-50033; 2-methylimidazol; 2-metylimidazole; 2-Methylimdazole; HSDB 7756; 2-methyl-imidazol; 2-methyl-imidazole; 2-Methyl glyoxaline; 2-methyl-1h-imidazol; CUREZOL-2MZ-P; IMICURE-AMI 2; EPICURE-MI 2; EPIKURE-MI 2; 2-Methylimidazole-[d5]; 2-Methylimidazole, 99%; RESICURE(TM) 46; EC 211-765-7; METHYLIMIDAZOLE, 2-; WLN: T5M CNJ B1; MLS001065618; 2-METHYLIMIDAZOLE [HSDB]; 2-METHYLIMIDAZOLE [IARC]; HMS3039F06; NSC21394; STR02220; ZINC8283844; Tox21_111136; Tox21_201316; Tox21_302808; BBL013047; BDBM50295560; STK301707; AKOS000118836; CS-W019983; PB43299; NCGC00091456-02; NCGC00256531-01; NCGC00258868-01; SMR000568464; 2-Methylimidazole (Ondansetron Impurity F); AM20100647; FT-0613056; FT-0671849; M0345; EN300-21278; C19261; D77862; A833348; A836474; W-104630; Q21099566; F2190-0640; Z104494990; ONDANSETRON HYDROCHLORIDE DIHYDRATE IMPURITY F [EP IMPURITY]; 2-Methylimidazole, >=95.0% (HPLC), pharmaceutical impurity standard; Ondansetron impurity F, European Pharmacopoeia (EP) Reference Standard; ONDANSETRON HYDROCHLORIDE IMPURITY, 2-METHYLIMIDAZOLE- [USP IMPURITY]; 2-Methylimidazole (Ondansetron Impurity F), Pharmaceutical Secondary Standard; Certified Reference Material